ADTL-EI1712 

ADTL-EI1712 is a potent, orally active, and selective dual-target inhibitor of ERK1 and ERK5, inhibition rates of ERK1/5 at 1 μM are 93.54% and 89.35%, respectively. ADTL-EI1712 can induce regulated cell death, a form of cell death that relies on the activation of genetically encoded machinery, to overcome compensatory mechanism in specific cancer cells in vitro and in vivo^[1].

ADTL-EI1712 shows antiproliferative activity against HL-60, MKN-74 and HeLa cells, with IC₅₀ values of 1.26+0.57, 2.55+0.66, >50 μM, respectively^[1].
ADTL-EI1712 (0.5 μM, 24 h) induces regulated cell death accompanied by autophagy in MKN-74 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ADTL-EI1712 (50 mg/kg, PO, once a day for 16 days) significantly inhibits the tumor volume in the xenograft mouse model of HL-60 and MKN-74 cells, while the antitumor effect of HeLa cells group was much weaker^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

505.44

C₂₂H₁₈Cl₂N₄O₂S₂

2414916-45-1

O=C(C1=C(NC(C2=CC=CC=C2Cl)=O)SC3=C1CCN(C(NC4=CC=CC=C4Cl)=S)C3)N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang G, et al. Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types. J Med Chem. 2020 Apr 23;63(8):3976-3995.  [Content Brief]